284 related articles for article (PubMed ID: 34680734)
1. Beta-Lactams Dosing in Critically Ill Patients with Gram-Negative Bacterial Infections: A PK/PD Approach.
Maguigan KL; Al-Shaer MH; Peloquin CA
Antibiotics (Basel); 2021 Sep; 10(10):. PubMed ID: 34680734
[TBL] [Abstract][Full Text] [Related]
2. Role of a Real-Time TDM-Based Expert Clinical Pharmacological Advice Program in Optimizing the Early Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Beta-Lactams among Orthotopic Liver Transplant Recipients with Documented or Suspected Gram-Negative Infections.
Gatti M; Rinaldi M; Laici C; Siniscalchi A; Viale P; Pea F
Antibiotics (Basel); 2023 Nov; 12(11):. PubMed ID: 37998801
[TBL] [Abstract][Full Text] [Related]
3. Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams.
Gatti M; Pea F
Expert Rev Anti Infect Ther; 2023 Feb; 21(2):149-166. PubMed ID: 36655779
[TBL] [Abstract][Full Text] [Related]
4. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
[TBL] [Abstract][Full Text] [Related]
5. Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach for Maximizing the Effectiveness of Monotherapy Even in the Treatment of Critically Ill Patients with Documented Extended-Spectrum Beta-Lactamase-Producing
Gatti M; Rinaldi M; Tonetti T; Siniscalchi A; Viale P; Pea F
Antibiotics (Basel); 2023 Dec; 12(12):. PubMed ID: 38136770
[TBL] [Abstract][Full Text] [Related]
6. Optimising β -lactam Dosing in Neonates: A Review of Pharmacokinetics, Drug Exposure and Pathogens.
Fuchs A; Li G; van den Anker JN; Bielicki J
Curr Pharm Des; 2017; 23(38):5805-5838. PubMed ID: 28950814
[TBL] [Abstract][Full Text] [Related]
7. Prolonged administration of β-lactam antibiotics - a comprehensive review and critical appraisal.
Osthoff M; Siegemund M; Balestra G; Abdul-Aziz MH; Roberts JA
Swiss Med Wkly; 2016; 146():w14368. PubMed ID: 27731492
[TBL] [Abstract][Full Text] [Related]
8. The Pharmacodynamics of Prolonged Infusion β-Lactams for the Treatment of Pseudomonas aeruginosa Infections: A Systematic Review.
Thabit AK; Hobbs ALV; Guzman OE; Shea KM
Clin Ther; 2019 Nov; 41(11):2397-2415.e8. PubMed ID: 31679822
[TBL] [Abstract][Full Text] [Related]
9. Assessment of a PK/PD Target of Continuous Infusion Beta-Lactams Useful for Preventing Microbiological Failure and/or Resistance Development in Critically Ill Patients Affected by Documented Gram-Negative Infections.
Gatti M; Cojutti PG; Pascale R; Tonetti T; Laici C; Dell'Olio A; Siniscalchi A; Giannella M; Viale P; Pea F
Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827249
[TBL] [Abstract][Full Text] [Related]
10. Time Above All Else: Pharmacodynamic Analysis of β-Lactams in Critically Ill Patients.
Landmesser KB; Clark JA; Burgess DS
J Clin Pharmacol; 2022 Apr; 62(4):479-485. PubMed ID: 34614542
[TBL] [Abstract][Full Text] [Related]
11. Impact of attaining aggressive vs. conservative PK/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysis.
Gatti M; Cojutti PG; Pea F
Crit Care; 2024 Apr; 28(1):123. PubMed ID: 38627763
[TBL] [Abstract][Full Text] [Related]
12. Continuous infusion of beta-lactam antibiotics.
MacGowan AP; Bowker KE
Clin Pharmacokinet; 1998 Nov; 35(5):391-402. PubMed ID: 9839090
[TBL] [Abstract][Full Text] [Related]
13. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
Peric M; Browne FA; Jacobs MR; Appelbaum PC
Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
[TBL] [Abstract][Full Text] [Related]
14. A Population Pharmacokinetics and Pharmacodynamic Approach To Optimize Tazobactam Activity in Critically Ill Patients.
Kalaria SN; Gopalakrishnan M; Heil EL
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871076
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients.
Veiga RP; Paiva JA
Crit Care; 2018 Sep; 22(1):233. PubMed ID: 30244674
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of studies on extended versus standard infusion of beta-lactam antibiotics.
Chen M; Buurma V; Shah M; Fahim G
Am J Health Syst Pharm; 2019 Sep; 76(18):1383-1394. PubMed ID: 31505562
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors.
Gatti M; Pea F
Expert Rev Clin Pharmacol; 2021 May; 14(5):583-599. PubMed ID: 33687300
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients.
De Waele JJ; Lipman J; Akova M; Bassetti M; Dimopoulos G; Kaukonen M; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Udy AA; Starr T; Wallis SC; Roberts JA
Intensive Care Med; 2014 Sep; 40(9):1340-51. PubMed ID: 25053248
[TBL] [Abstract][Full Text] [Related]
19. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
[TBL] [Abstract][Full Text] [Related]
20. Prolonged infusion of beta-lactam antibiotics for Gram-negative infections: rationale and evidence base.
Abdul-Aziz MH; Portunato F; Roberts JA
Curr Opin Infect Dis; 2020 Dec; 33(6):501-510. PubMed ID: 33009140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
